<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Common combination oral contraceptive options, androgenicity, and associated venous thromboembolic risk of the progestin component</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Common combination oral contraceptive options, androgenicity, and associated venous thromboembolic risk of the progestin component</h1>
<div class="graphic"><div class="figure"><div class="ttl">Common combination oral contraceptive options, androgenicity, and associated venous thromboembolic risk of the progestin component</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup> <colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Progestin component</td> <td class="subtitle1">Progestin androgenicity</td> <td class="subtitle1">Relative VTE risk <span class="nowrap_whitespace">of COC<sup>*</sup><sup>[1,2]</sup></span></td> <td class="subtitle1">Absolute VTE risk <span class="nowrap_whitespace">of COC<sup>¶</sup><sup>[1-4]</sup></span></td> <td class="subtitle1">Select formulations<sup>Δ</sup></td> </tr> <tr> <td>Norgestimate</td> <td>Neutral or weak androgen</td> <td>2.5</td> <td>6</td> <td>Norgestimate 0.25 mg/ethinyl estradiol <span class="nowrap_whitespace">35 mcg:</span> <ul class="decimal_heading"> <li>Brand names: Estarylla, Femynor, Mili, Mono-Linyah, Nymyo, <span class="nowrap_whitespace">Sprintec 28,</span> VyLibra</li> </ul> </td> </tr> <tr> <td>Drospirenone</td> <td>Antiandrogen</td> <td>4.1</td> <td>13</td> <td>Drospirenone 3 mg/ethinyl estradiol <span class="nowrap_whitespace">30 mcg:</span> <ul class="decimal_heading"> <li>Brand names: Ocella, Safyral, Syeda, Tydemy, Yasmin, Zumandimine</li> </ul> </td> </tr> <tr> <td>Levonorgestrel</td> <td>Weak androgen</td> <td>2.4</td> <td>6</td> <td>Levonorgestrel 0.15 mg/ethinyl estradiol <span class="nowrap_whitespace">30 mcg:</span> <ul class="decimal_heading"> <li>Brand names: Altavera, Ayuna, Chateal EQ, Kurvelo, <span class="nowrap_whitespace">Levora 0.15/30,</span> Marlissa, <span class="nowrap_whitespace">Portia-28</span></li> </ul> </td> </tr> <tr> <td>Norethindrone (norethisterone)</td> <td>Weak androgen</td> <td>2.6</td> <td>7</td> <td>Norethindrone-containing formulations (mg norethindrone/mg ethinyl estradiol): <ul class="decimal_heading"> <li>0.4 mg/35 mg: <ul> <li>Brand names: Balziva, Briellyn, Philith, Vyfemla, Wymzya Fe chewable tablets<sup>◊</sup></li> </ul> </li> <li>0.5 mg/35 mcg: <ul> <li>Brand names: <span class="nowrap_whitespace">Necon 0.5/35,</span> <span class="nowrap_whitespace">Nortrel 0.5/35,</span> Wera</li> </ul> </li> <li>1 mg/35 mcg: <ul> <li>Brand names: <span class="nowrap_whitespace">Alyacen 1/35,</span> <span class="nowrap_whitespace">Dasetta 1/35,</span> <span class="nowrap_whitespace">Nortrel 1/35,</span> <span class="nowrap_whitespace">Nylia 1/35,</span> <span class="nowrap_whitespace">Pirmella 1/35</span></li> </ul> </li> </ul> <p class="extra_spacing_top"> <br/> Norethindrone acetate 1.5 mg/ethinyl estradiol <span class="nowrap_whitespace">30 mcg:</span></p> <ul class="decimal_heading"> <li>Brand names: <span class="nowrap_whitespace">Aurovela 1.5/30,</span> <span class="nowrap_whitespace">Aurovela Fe 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Blisovi Fe 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Junel 1.5/30,</span> <span class="nowrap_whitespace">Junel FE 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Hailey 1.5/30,</span> <span class="nowrap_whitespace">Hailey FE 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Larin 1.5/30,</span> <span class="nowrap_whitespace">Larin Fe 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Loestrin 1.5/30,</span> <span class="nowrap_whitespace">Loestrin Fe 1.5/30<sup>◊</sup>,</span> <span class="nowrap_whitespace">Microgestin 1.5/30,</span> <span class="nowrap_whitespace">Microgestin FE 1.5/30<sup>◊</sup></span></li> </ul> </td> </tr> <tr> <td>Desogestrel</td> <td>Neutral</td> <td>4.3</td> <td>14</td> <td>Desogestrel 0.15 mg/ethinyl estradiol <span class="nowrap_whitespace">30 mcg:</span> <ul class="decimal_heading"> <li>Brand names: Apri, Cyred, Cyred EQ, Enskyce, Isibloom, Juleber, Kalliga, Reclipsen</li> </ul> </td> </tr> <tr> <td>Gestodene</td> <td>Neutral</td> <td>3.6</td> <td>11</td> <td>Gestodene 0.75 mg/ethinyl estradiol <span class="nowrap_whitespace">30 mcg<sup>§</sup>:</span> <ul class="decimal_heading"> <li>Brand names: Akizza, Femodene, <span class="nowrap_whitespace">Millinette (30/75),</span> Minulet</li> </ul> </td> </tr> <tr> <td>Cyproterone acetate</td> <td>Antiandrogen</td> <td>4.3</td> <td>14</td> <td>Cyproterone acetate 2 mg/ethinyl estradiol <span class="nowrap_whitespace">35 mcg<sup>§</sup>:</span> <ul class="decimal_heading"> <li>Brand names: <span class="nowrap_whitespace">Cleo-35,</span> Co-ciprindiol, <span class="nowrap_whitespace">Cyestra-35,</span> <span class="nowrap_whitespace">Diane-35,</span> Dianette, Estelle</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table presents several COCs along with the androgenicity and VTE risk of their progestin component.</div><div class="graphic_footnotes"><p>COC: combination oral contraceptive; VTE: venous thromboembolism.</p>
<p>* Relative VTE risk is compared with patients who are not using oral contraceptives.</p>
<p>¶ Extra cases of VTE per 10,000 women treated with COCs per year.</p>
<p>Δ For treatment of polycystic ovary syndrome in adolescents, UpToDate authors prefer COCs with at least 30 mcg of ethinyl estradiol; this table lists a selection of such formulations with example brand names available in the United States. Adults with polycystic ovary syndrome may be managed differently; refer to related UpToDate content. COC formulations with less estrogen, multiphasic combinations, and extended cycle combinations are also available; refer to related UpToDate content.</p>
<p>◊ Packaged with ferrous fumarate instead of inactive (placebo) pills.</p>
§ Not available in the United States; example formulations are available elsewhere in the world. Refer to local prescribing information.</div><div class="graphic_reference">References:
<ol>
<li>Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynecol Obstet 2018; 141: 287-294.</li>
<li>Vinogradova Y, Coupland C, and Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350:h2135.</li>
<li>Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: Systematic review and network meta-analysis. BMJ 2013; 347:f5298.</li>
<li>Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103:1233.</li>
</ol></div><div id="graphicVersion">Graphic 110726 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
